Urolithiasis Management Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy, Others), By End Use (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region, and By Competition, 2020-2030F

Market Overview

The Global Urolithiasis Management Devices Market, valued at USD 2.01 Billion in 2024, is projected to experience a CAGR of 4.97% to reach USD 2.69 Billion by 2030. Urolithiasis management devices encompass a range of medical instruments essential for the diagnosis, treatment, and prevention of kidney stones and other urinary tract calculi. This market experiences robust growth primarily driven by the increasing global prevalence of urolithiasis, coupled with a growing preference for minimally invasive surgical procedures that offer enhanced patient outcomes and reduced recovery times. Advancements in medical technologies, including sophisticated laser lithotripters and flexible ureteroscopes, further stimulate market expansion by providing more effective stone fragmentation and removal solutions. According to the Urologic Diseases in America: Annual Data Report 2024 from the National Institutes of Health, the claims-based prevalence of urinary stone disease among persons aged 18-64 in the United States was 1-2% annually from 2012 to 2021, rising to 3-5% for those aged 65 and older.

However, the market faces significant impediments, including the high cost associated with advanced devices and surgical interventions. This financial burden can restrict widespread adoption, particularly in developing regions with limited healthcare resources and inadequate insurance coverage, thereby challenging overall market expansion. The shortage of skilled urologists in some geographical areas also poses an adoption barrier for complex procedures requiring specialized expertise.

Key Market Drivers

The rising global burden of urolithiasis primarily drives the Global Urolithiasis Management Devices Market, with increasing prevalence expanding the patient population needing intervention. Shifting lifestyles, dietary habits, and metabolic disorders contribute to this growing caseload. According to "The global, regional, and national burden of urolithiasis in 204 countries and territories, 2000–2021: a systematic analysis for the Global Burden of Disease Study 2021" via ResearchGate, in November 2024, there were 106 million incident cases of urolithiasis in 2021. This incidence ensures consistent demand for detection, treatment, and prevention instruments, stimulating market growth. The broader urology devices market reflects robust strategic investment; HealthLeaders Media reported in January 2024 that Boston Scientific acquired Axonics for $3.7 billion, underscoring significant financial commitments.

Advancements in minimally invasive treatment technologies critically influence market expansion, driven by clinical preference for improved patient outcomes and shorter recovery. Innovations include precise laser systems, enhanced flexible ureteroscopes, and sophisticated robotic-assisted surgical platforms. This progress facilitates efficient stone fragmentation, superior intraoperative visualization, and access to challenging anatomical areas, enhancing management effectiveness and safety. Increasing adoption of these techniques by clinicians reinforces market demand for continuous innovation. A study published in "Robotics" via the American Urological Association, in February 2024, reported over 12 million robotic surgical procedures performed globally, with more than 60,000 surgeons trained on the da Vinci system, illustrating widespread integration into urological practice.

Download Free Sample Report

Key Market Challenges

The high cost associated with advanced urolithiasis management devices and surgical interventions presents a significant impediment to market growth. This financial burden directly restricts widespread adoption, particularly in developing regions where healthcare budgets are limited and patient out-of-pocket expenses are substantial. The investment required for advanced equipment, such as laser lithotripters and flexible ureteroscopes, can be prohibitive for many healthcare facilities. This limitation curtails the market penetration of innovative solutions, thereby reducing potential sales and usage in areas with a high prevalence of urinary tract calculi.

This economic challenge is exacerbated by prevailing healthcare funding models. According to the World Health Organization's 2024 Global Spending on Health report, published in December 2024, 43% of all health spending was out of pocket in low-income countries in 2022, compared to 19% in high-income countries. Such reliance on direct patient payments severely limits access to costly, specialized procedures and devices, preventing a substantial segment of the global patient population from receiving optimal care. Consequently, the overall demand for advanced urolithiasis management devices is suppressed in these critical growth markets.

Key Market Trends

The increasing shift of urological procedures to Ambulatory Surgical Centers (ASCs) is a significant trend impacting the global urolithiasis management devices market. This trend is driven by the advantages ASCs offer, such as cost-effectiveness for patients and healthcare systems, shorter waiting times, and a more streamlined patient experience compared to traditional hospital settings. As procedures become less invasive and technological advancements facilitate outpatient care, more complex urological interventions, including certain stone removal procedures, are being safely performed in ASCs. According to a March 2025 report from MedPAC, the volume of ASC surgical procedures per fee-for-service Medicare beneficiary rose by 5.7 percent in 2023. This expansion directly influences device manufacturers to adapt their sales and distribution strategies to cater to the unique procurement and inventory management needs of ASCs, fostering demand for devices optimized for outpatient use.

The increasing adoption of disposable urolithiasis devices represents another key trend, driven primarily by enhanced infection control, consistent performance, and reduced reprocessing burdens. Single-use devices eliminate the risks associated with inadequate sterilization or damage from repeated use, which can compromise patient safety and procedural efficacy. Healthcare facilities are increasingly prioritizing these devices to mitigate infection risks and streamline operational workflows, despite their potentially higher upfront cost. Olympus announced in April 2024 the U. S. FDA 510(k) clearance of RenaFlex, its first single-use flexible ureteroscope system, indicating a strategic move by major players into this growing segment. This trend encourages innovation in disposable technologies, leading to the development of instruments that offer improved visualization, maneuverability, and therapeutic capabilities, thereby supporting the overall growth and technological advancement within the urolithiasis management devices market.

Segmental Insights

The Intracorporeal Lithotripsy segment is experiencing rapid growth within the Global Urolithiasis Management Devices Market, driven by its significant procedural advantages and technological evolution. This method offers enhanced precision in stone fragmentation within the urinary tract, leading to high stone-free rates and improved patient outcomes. The increasing global incidence of urolithiasis, coupled with a growing patient preference for minimally invasive procedures due to benefits such as reduced recovery times and shorter hospital stays, further fuels this expansion. Continuous advancements in device technology, including more efficient energy sources and improved imaging, contribute to its increasing adoption over traditional treatment alternatives.

Regional Insights

North America leads the global urolithiasis management devices market due to a convergence of critical factors. The region exhibits a high prevalence and incidence of kidney stone formations, as highlighted by organizations like the American Urological Association, which drives consistent demand for treatment devices. This is further supported by advanced healthcare infrastructure and a proactive adoption of innovative, minimally invasive surgical techniques such as laser lithotripsy and ureteroscopy, which offer reduced recovery times. Additionally, high patient awareness regarding available treatment options, coupled with favorable reimbursement policies, significantly contributes to North America's market dominance.

Recent Developments

• In September 2025, Dornier MedTech America initiated the full U.S. commercialization of two novel single-use urology devices: the Hoover™ ureteral access sheath and the Axis® II Slim single-use ureteroscope. These devices, which had previously received FDA clearance and limited release, are engineered to function synergistically with the company's Thulio pulsed Thulium:YAG laser system. This integrated platform aims to provide a comprehensive solution for flexible ureteroscopy procedures, specifically for kidney stone management. The Hoover sheath is designed for enhanced suction performance and deflection, while the Axis II Slim ureteroscope offers improved maneuverability, facilitating access and minimizing trauma during complex stone procedures.

• In July 2024, OmniGuide Holdings, Inc. announced the successful completion of a pivotal patient study for its iSTONE™ software, a laser-guided system designed for real-time automatic target identification during endoscopic stone lithotripsy. This breakthrough research aims to advance the treatment of urolithiasis by enhancing precision and safety in kidney stone management procedures. The iSTONE technology features a novel optical feedback mechanism, which in preclinical studies demonstrated a significant reduction in the energy required for lithotripsy. This innovation is intended to minimize thermal load and potential temperature increase within the kidney, thereby preserving organ integrity and reducing the risk of postoperative damage.

• In June 2024, Dymium, a German company, was recognized with the audience-voted Alex Casta Award at the EIT Health Catapult program for its breakthrough research in magnetism-based residue-free extraction of kidney stones. This innovative approach represents a significant advancement in urolithiasis management devices, aiming to provide a cleaner and more efficient method for removing stone fragments. The technology focuses on improving patient outcomes by ensuring minimal residual stone burden, which can reduce the need for repeat procedures and associated complications. This recognition highlights the potential for novel physics-based solutions in enhancing current kidney stone treatment paradigms.

• In April 2024, Olympus showcased its RenaFlex™ single-use flexible ureteroscope system at the American Urological Association annual meeting. This product launch represented Olympus's introduction of its first single-use flexible ureteroscope, intended for visualizing urinary tract organs, cavities, and canals. The RenaFlex system, which received FDA clearance prior to its limited market launch in 2024, also supports various diagnostic and therapeutic procedures within the urinary tract when combined with compatible endoscopic accessories. This development expands Olympus's urology portfolio, offering healthcare professionals a new tool for managing urinary stones.

Key Market Players

• Allengers Medical Systems Ltd
• Boston Scientific Corp
• Cook Medical Inc
• CONMED Corp
• DiREX Group
• Dornier MedTech GmbH
• HealthTronics Inc
• Karl Storz SE & Co KG
• Lumenis Inc
• Siemens Healthcare Ltd

Report Scope:

In this report, the Global Urolithiasis Management Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Urolithiasis Management Devices Market, By Treatment Type:

o   Extracorporeal Shock Wave Lithotripsy (ESWL)

o   Intracorporeal Lithotripsy

o   Percutaneous Nephrolithotomy

o   Others

• Urolithiasis Management Devices Market, By End Use:

o   Hospitals & Clinics

o   Ambulatory Surgical Centers

o   Others

• Urolithiasis Management Devices Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Urolithiasis Management Devices Market.

Available Customizations:

Global Urolithiasis Management Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Urolithiasis Management Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]